Macrogen was established on June 5, 1997, based in the Genomic Medicine Institute of the Seoul National University College of Medicine. In February 2000. It is the first Korean bio venture to be listed on the KOSDAQ.

Since then, Macrogen has continued to be actively engaged in R&D fields for genetic and genomic analyses. In addition to providing services to clients around the world, Macrogen contributes to the advancement of bioindustries through a wide range of CSR activities.

Macrogen is committed to leading innovation in precision medicine in the 21st century by providing personalized genomic information. It is also realizing achievements in the global genome analysis market in various sectors, thanks to its superior technological expertise.